These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 37343159)

  • 1. Comparative efficacy of novel-drugs combined therapeutic regimens on relapsed/refractory multiple myeloma: a network meta-analysis.
    Chen H; Chen H; Zhou Y; Xu W; Yu J; Xu Y; Zhou F
    Hematology; 2023 Dec; 28(1):2225342. PubMed ID: 37343159
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of relapsed/refractory multiple myeloma in the bortezomib and lenalidomide era: a systematic review and network meta-analysis.
    Arcuri LJ; Americo AD
    Ann Hematol; 2021 Mar; 100(3):725-734. PubMed ID: 33432438
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Network meta-analysis of efficacy of ixazomib, lenalidomide, and dexamethasone in relapsed/refractory multiple myeloma.
    DerSarkissian M; Cranmer H; Dabora J; Bocharova I; Cherepanov D; Cheng M; Bhak RH; Duh MS
    Hematology; 2023 Dec; 28(1):2156731. PubMed ID: 36607147
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of adverse events and associated cost with efficacy for approved relapsed and/or refractory multiple myeloma regimens: A Bayesian network meta-analysis of phase 3 randomized controlled trials.
    Dhakal B; Narra RK; Giri S; Szabo A; Smunt TL; Ghose S; Pathak LK; Aryal M; Hamadani M; Chhabra S; Janz S; D'Souza A; Hari PN
    Cancer; 2020 Jun; 126(12):2791-2801. PubMed ID: 32154922
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Systematic Review and Network Meta-analysis of Randomized Data on Efficacy of Novel Therapy Combinations in Patients with Lenalidomide-refractory Multiple Myeloma.
    Mohyuddin GR; Hampton J; Aziz M; Khuder S; Malik S; McClune B; Abdallah AO
    Clin Lymphoma Myeloma Leuk; 2021 Jul; 21(7):489-496. PubMed ID: 33962898
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multinomial network meta-analysis using response rates: relapsed/refractory multiple myeloma treatment rankings differ depending on the choice of outcome.
    van Beurden-Tan CHY; Sonneveld P; Groot CAU
    BMC Cancer; 2022 May; 22(1):591. PubMed ID: 35637452
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of selinexor-based regimens for relapsed/refractory multiple myeloma: a systematic review of literature.
    Masood A; Iqbal Q; Ehsan H; Davis JA; Hansen DK; Hashmi H
    Ann Hematol; 2022 Dec; 101(12):2601-2610. PubMed ID: 36214853
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical efficacy of daratumumab, pomalidomide, and dexamethasone in patients with relapsed or refractory myeloma: Utility of re-treatment with daratumumab among refractory patients.
    Nooka AK; Joseph NS; Kaufman JL; Heffner LT; Gupta VA; Gleason C; Boise LH; Lonial S
    Cancer; 2019 Sep; 125(17):2991-3000. PubMed ID: 31090928
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Isatuximab: A Review of Its Use in Multiple Myeloma.
    Frampton JE
    Target Oncol; 2021 Sep; 16(5):675-686. PubMed ID: 34351561
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment Options for Patients With Heavily Pretreated Relapsed and Refractory Multiple Myeloma.
    Dimopoulos MA; Richardson P; Lonial S
    Clin Lymphoma Myeloma Leuk; 2022 Jul; 22(7):460-473. PubMed ID: 35148975
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-world comparative effectiveness of triplets containing bortezomib (B), carfilzomib (C), daratumumab (D), or ixazomib (I) in relapsed/refractory multiple myeloma (RRMM) in the US.
    Davies F; Rifkin R; Costello C; Morgan G; Usmani S; Abonour R; Palumbo A; Romanus D; Hajek R; Terpos E; Cherepanov D; Stull DM; Huang H; Leleu X; Berdeja J; Lee HC; Weisel K; Thompson M; Boccadoro M; Zonder J; Cook G; Puig N; Vela-Ojeda J; Farrelly E; Raju A; Blazer M; Chari A
    Ann Hematol; 2021 Sep; 100(9):2325-2337. PubMed ID: 33970288
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systematic Literature Review and Network Meta-Analysis of Treatment Outcomes in Relapsed and/or Refractory Multiple Myeloma.
    van Beurden-Tan CHY; Franken MG; Blommestein HM; Uyl-de Groot CA; Sonneveld P
    J Clin Oncol; 2017 Apr; 35(12):1312-1319. PubMed ID: 28240968
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Comparison of the Efficacy of Immunomodulatory-containing Regimens in Relapsed/Refractory Multiple Myeloma: A Network Meta-analysis.
    Dimopoulos MA; Kaufman JL; White D; Cook G; Rizzo M; Xu Y; Fahrbach K; Gaudig M; Slavcev M; Dearden L; Lam A
    Clin Lymphoma Myeloma Leuk; 2018 Mar; 18(3):163-173.e6. PubMed ID: 29456035
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An evaluation of isatuximab, pomalidomide and dexamethasone for adult patients with relapsed and refractory multiple myeloma.
    Piggin A; Prince HM
    Expert Rev Hematol; 2021 May; 14(5):419-427. PubMed ID: 33945375
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selinexor for the treatment of patients with relapsed or refractory multiple myeloma.
    Babar A; Babar M; Zubair H; Shahid A; Rafique S; Bano M; Waleed MS; Khan M; Inayat A; Safi D
    J Oncol Pharm Pract; 2024 Apr; 30(3):535-546. PubMed ID: 38454813
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond.
    Chim CS; Kumar SK; Orlowski RZ; Cook G; Richardson PG; Gertz MA; Giralt S; Mateos MV; Leleu X; Anderson KC
    Leukemia; 2018 Feb; 32(2):252-262. PubMed ID: 29257139
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of the Efficacy of Thalidomide Plus Dexamethasone-Based Regimens in Patients With Relapsed/Refractory Multiple Myeloma Who Received Prior Chemotherapy, Including Bortezomib and Lenalidomide: KMM-166 Study.
    Jung KS; Kim K; Kim HJ; Kim SH; Lee JO; Kim JS; Lee JJ; Eom HS; Min CK; Shin HJ
    Clin Lymphoma Myeloma Leuk; 2020 Feb; 20(2):e97-e104. PubMed ID: 31831372
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relapsed and refractory multiple myeloma: A systematic review and network meta-analysis of the efficacy of novel therapies.
    Minakata D; Fujiwara SI; Yokoyama D; Noguchi A; Aoe S; Oyama T; Koyama S; Murahashi R; Nakashima H; Hyodo K; Ikeda T; Kawaguchi SI; Toda Y; Ito S; Nagayama T; Mashima K; Umino K; Morita K; Ashizawa M; Yamamoto C; Hatano K; Sato K; Ohmine K; Kanda Y
    Br J Haematol; 2023 Mar; 200(6):694-703. PubMed ID: 36661264
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comprehensive overview of daratumumab and carfilzomib and the recently approved daratumumab, carfilzomib and dexamethasone regimen in relapsed/refractory multiple myeloma.
    Richard S; Jagannath S; Cho HJ; Parekh S; Madduri D; Richter J; Chari A
    Expert Rev Hematol; 2021 Jan; 14(1):31-45. PubMed ID: 33331794
    [No Abstract]   [Full Text] [Related]  

  • 20. Cost-effectiveness of Daratumumab-based Triplet Therapies in Patients With Relapsed or Refractory Multiple Myeloma.
    Zhang TT; Wang S; Wan N; Zhang L; Zhang Z; Jiang J
    Clin Ther; 2018 Jul; 40(7):1122-1139. PubMed ID: 30006069
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.